Brian G. Till M.D.

 Brian  G. Till M.D.

Bio

Dr. Till is an assistant member at Fred Hutch and an assistant professor at UW. He specializes in lymphoma and stem cell transplantation. Dr. Till also…

Read Full Bio

Patient Care Philosophy

I believe that good communication with my patients is essential; I strive to tailor the treatment to their individual needs based on the best clinical evidence. Additionally, I want to raise the bar on the current standard of care and provide cutting edge treatments by encouraging patients to participate in clinical trials.

Personal Interests

Spending time with my family, eating good food, brewing beer and hiking.

Clinical Interests

Lymphoma and autologous stem cell transplantation for lymphoma and myeloma.

Research Interests

Clinical and laboratory research in CAR T cell therapy (using gene therapy to train patients' immune cells to attack their lymphomas).

Education

InstitutionCredentialYear
Univ. of ChicagoMedical education2002
Fred Hutchinson Cancer Research CenterFellowship
Hosp. of the Univ. of PA (General Medicine)Internship
Hosp. of the Univ. of PA (General Medicine)Residency

DegreeDescriptionYear
MD2002

Board Certifications

CertificationSpecialtyYear
American Board of Internal MedicineMedical Oncology2008
American Board of Internal MedicineGeneral Internal Medicine2005
Dr. Till is an assistant member at Fred Hutch and an assistant professor at UW. He specializes in lymphoma and stem cell transplantation.

Dr. Till also conducts research on developing new immunotherapies for lymphoma, with a focus on using patients' own T cells to fight their lymphomas, using genetically engineered cells with chimeric antigen receptors(CARs).

Dr. Till earned his M.D. from the University of Chicago, then received internal medicine training with a residency at the University of Pennsylvania. He then came to Seattle to specialize in oncology with a fellowship at Fred Hutch and the UW.

He is board certified in medical oncology and is a member of the SWOG national clinical trials group, the American Society of Hematology, the National Cancer Institute Clinical Trials Planning Meetings (Lymphoma Steering Committee). He has received research funding from the American Society of Clinical Oncology, Lymphoma Research Foundation, Damon Runyon Cancer Research Foundation and the National Cancer Institute.

Provider Locations